Safety and Efficacy of Antiplatelet and Antithrombotic Therapy in Acute Coronary Syndrome Patients With Chronic Kidney Disease

被引：46

作者：

Basra, Sukhdeep S. ^{[2
]}

Tsai, Peter ^{[3
]}

Lakkis, Nasser M. ^{[1
,2
]}

机构：

[1] Baylor Coll Med, Cardiol Sect, Dept Med, Houston, TX 77030 USA

[2] Baylor Coll Med, Dept Internal Med, Houston, TX 77030 USA

[3] Baylor Coll Med, Sect Cardiothorac Surg, Dept Surg, Houston, TX 77030 USA

来源：

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY | 2011年 / 58卷 / 22期

关键词：

acute coronary syndrome(s); antiplatelet; antithrombotic; bleeding; chronic kidney disease; non-ST-segment elevation myocardial infarction; ST-segment elevation myocardial infarction; unstable angina; ST-SEGMENT ELEVATION; WAVE MYOCARDIAL-INFARCTION; MOLECULAR-WEIGHT HEPARIN; STAGE RENAL-DISEASE; HIGH-RISK PATIENTS; GLYCOPROTEIN IIB/IIIA INHIBITORS; UNFRACTIONATED HEPARIN; ARTERY-DISEASE; DOUBLE-BLIND; PLATELET INHIBITION;

D O I：

10.1016/j.jacc.2011.08.051

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with CKD have a higher risk of ACS and significantly higher mortality, and are also predisposed to increased bleeding complications. Antiplatelet and antithrombotic drugs form the bedrock of management of patients with ACS. Most randomized trials of these drugs exclude patients with CKD, and current guidelines for management of these patients are largely based on these trials. We aim to review the safety and efficacy of these drugs in patients with CKD presenting with ACS. (J Am Coll Cardiol 2011;58:2263-9) (C) 2011 by the American College of Cardiology Foundation

引用

页码：2263 / 2269

页数：7

共 71 条

[31] Combining enoxaparin and glycoprotein IIb/IIIa antagonists for the treatment of acute coronary syndromes: Final results of the National Investigators Collaborating on Enoxaparin-3 (NICE-3) study [J].

Ferguson, JJ ;

Antman, EM ;

Bates, ER ;

Cohen, M ;

Every, NR ;

Harrington, RA ;

Pepine, CJ ;

Theroux, P .

AMERICAN HEART JOURNAL, 2003, 146 (04) :628-634

[32] Use of Evidence-Based Therapies in Short-Term Outcomes of ST-Segment Elevation Myocardial Infarction and Non-ST-Segment Elevation Myocardial Infarction in Patients With Chronic Kidney Disease A Report From the National Cardiovascular Data Acute Coronary Treatment and Intervention Outcomes Network Registry [J].

Fox, Caroline S. ;

Muntner, Paul ;

Chen, Anita Y. ;

Alexander, Karen P. ;

Roe, Matthew T. ;

Cannon, Christopher P. ;

Saucedo, Jorge F. ;

Kontos, Michael C. ;

Wiviott, Stephen D. .

CIRCULATION, 2010, 121 (03) :357-U33

[33] Influence of renal function on the efficacy and safety of fondaparinux relative to enoxaparin in non-ST-segment elevation acute coronary syndromes [J].

Fox, Keith A. A. ;

Bassand, Jean-Pierre ;

Mehta, Shamir R. ;

Wallentin, Lars ;

Theroux, Pierre ;

Piegas, Leopoldo Soares ;

Valentin, Vicent ;

Moccetti, Tiziano ;

Chrolavicius, Susan ;

Afzal, Rizwan ;

Yusuf, Salim .

ANNALS OF INTERNAL MEDICINE, 2007, 147 (05) :304-310

[34] The impact of renal dysfunction on outcomes in the ExTRACT-TIMI 25 trial [J].

Fox, Keith A. A. ;

Antman, Elliott M. ;

Montalescot, Gilles ;

Agewall, Stefan ;

SomaRaju, Bhupathi ;

Verheugt, Freek W. A. ;

Lopez-Sendon, Jose ;

Hod, Hanoch ;

Murphy, Sabina A. ;

Braunwald, Eugene .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (23) :2249-2255

[35] Influence of concurrent renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the use of glycoprotein IIb/IIIa inhibitors [J].

Freeman, RV ;

Mehta, RH ;

Al Badr, W ;

Cooper, JV ;

Kline-Rogers, E ;

Eagle, KA .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (05) :718-724

[36] Comparison of efficacy and complication rates after percutaneous coronary interventions in patients with and without renal insufficiency treated with Abciximab [J].

Frilling, B ;

Zahn, R ;

Fraiture, B ;

Mark, B ;

Dönges, K ;

Becker, T ;

Siegler, KE ;

Seidl, K ;

Rustige, J ;

Senges, J .

AMERICAN JOURNAL OF CARDIOLOGY, 2002, 89 (04) :450-+

[37] Enoxaparin and bleeding complications: A review in patients with and without renal insufficiency [J].

Gerlach, AT ;

Pickworth, KK ;

Seth, SK ;

Tanna, SB ;

Barnes, JF .

PHARMACOTHERAPY, 2000, 20 (07) :771-775

[38] Heparin dosing and outcome in acute coronary syndromes: The GUSTO-IIb experience [J].

Gilchrist, IC ;

Berkowitz, SD ;

Thompson, TD ;

Califf, RM ;

Granger, CB .

AMERICAN HEART JOURNAL, 2002, 144 (01) :73-80

[39] Recombinant nematode anticoagulant protein c2 in patients with non-ST-Segment elevation acute coronary syndrome - The ANTHEM-TIMI-32 trial [J].

Giugliano, Robert P. ;

Wiviott, Stephen D. ;

Stone, Peter H. ;

Simon, Daniel I. ;

Schweiger, Marc J. ;

Bouchard, Alain ;

Leesar, Massoud A. ;

Goulder, Michael A. ;

Deitcher, Steven R. ;

McCabe, Carolyn H. ;

Braunwald, Eugene .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 49 (25) :2398-2407

[40] Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide [J].

Goodman, SG ;

Fitchett, D ;

Armstrong, PW ;

Tan, M ;

Langer, A .

CIRCULATION, 2003, 107 (02) :238-244

← 1 2 3 4 5 6 7 8 →